Bengaluru-based startup 4baseCare has announced a collaboration with Cellworks Group, a US-based company and world leader in personalised medicine in the key therapeutic areas of oncology and immunology.

As a part of this association, the organisations will further their capabilities in personalised cancer care and treatment strategy based on advanced clinical insights through genomics-based molecular profiling and biosimulation.

The collaboration aims to deliver greater insights to the oncology fraternity, predict patient therapy responses and enable therapy selection resulting in optimal treatment outcomes.

The comprehensive molecular insights of 4baseCare's TarGT Absolute test will be further advanced through Cellworks personalised cancer therapy predictions for front-line and refractory patients and will guide oncologists in India to select the optimal treatment strategy for each patient.

In addition, knowing each patient's response to therapies before treatment will enable oncologists to personalise drug selection, avoid unnecessary treatments and improve patient outcomes.